Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 120Tumor-Agnostic 3Other 2Gynecologic 2Endocrine 2

Conditions

Multiple Endocrine Neoplasia Type 1 2Sexual Dysfunction, Physiological 1Seizures 1Neoplasm Metastasis 1Hypogonadism 1Erectile Dysfunction 1Epilepsy 1

Interventions

Everolimus 32Octreotide 15Cisplatin 14pasireotide 13Sunitinib 13Temozolomide 11pembrolizumab 10Etoposide 10Doxorubicin 10lanreotide 9Magnetic Resonance Spectroscopy 9Bevacizumab 9lutetium Lu 177 dotatate 8gallium Ga 68 dotatate 8Sorafenib 8Paclitaxel 83-Iodobenzylguanidine 8lenvatinib 7pazopanib 6Radiotherapy 6Positron Emission Tomography Computed Tomography 6Nivolumab 6surufatinib 5cabozantinib 5avelumab 5Thyrotropin Alfa 5Surgical Procedures, Operative 5Radiosurgery 5Mitotane 5Irinotecan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Anastrozole × Endocrine × Clear all
NCT02753686 2023-02-15

Treat ER+ight

Novartis

Completed
440 enrolled
Endocrine

Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

NCT00179517 2019-07-17

Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo

Beth Israel Deaconess Medical Center

Phase 2 Completed
40 enrolled 13 charts
EndocrineOther

Epilepsy, Hypogonadism, Erectile Dysfunction, Seizures, Sexual Dysfunction, Physiological, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡